191 related articles for article (PubMed ID: 31512609)
1. Perils with Pirfenidone and "the tuberculosis link".
Hande MH; Acharya KV; Shreenivasa A; Nayak K; Arun S
Int J Mycobacteriol; 2019; 8(3):298-301. PubMed ID: 31512609
[TBL] [Abstract][Full Text] [Related]
2. Reactivation pulmonary tuberculosis in two patients treated with pirfenidone.
Khan M; Alghamdi M; Al-Jahdali H
Int J Mycobacteriol; 2017; 6(2):193-195. PubMed ID: 28559525
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone in idiopathic pulmonary fibrosis.
Maher TM
Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
[TBL] [Abstract][Full Text] [Related]
6. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
Valeyre D; Albera C; Bradford WZ; Costabel U; King TE; Leff JA; Noble PW; Sahn SA; du Bois RM
Respirology; 2014 Jul; 19(5):740-7. PubMed ID: 24836849
[TBL] [Abstract][Full Text] [Related]
8. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Anderson A; Shifren A; Nathan SD
Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012
[TBL] [Abstract][Full Text] [Related]
9. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
[TBL] [Abstract][Full Text] [Related]
10. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
11. Is pirfenidone effective for idiopathic pulmonary fibrosis?
Jeldres A; Labarca G
Medwave; 2017 Jan; 17(Suppl1):e6843. PubMed ID: 28112713
[TBL] [Abstract][Full Text] [Related]
12. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH; de Andrade JA; Zibrak JD; Padilla ML; Albera C; Nathan SD; Wijsenbeek MS; Stauffer JL; Kirchgaessler KU; Costabel U
Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29212837
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis].
Tokura T; Oku H; Tsukamoto Y
Nihon Yakurigaku Zasshi; 2009 Aug; 134(2):97-104. PubMed ID: 19672005
[No Abstract] [Full Text] [Related]
14. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
[TBL] [Abstract][Full Text] [Related]
16. Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis.
Fiddler CA; Simler N; Parfrey H; Miremadi A; Chilvers ER
Ann Am Thorac Soc; 2016 Aug; 13(8):1430-2. PubMed ID: 27509160
[No Abstract] [Full Text] [Related]
17. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
Glassberg MK; Nathan SD; Lin CY; Morgenthien EA; Stauffer JL; Chou W; Noble PW
Adv Ther; 2019 Oct; 36(10):2910-2926. PubMed ID: 31401786
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Poletti V; Ravaglia C; Tomassetti S
Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
[TBL] [Abstract][Full Text] [Related]
20. Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study.
Rahaghi FF; Safdar Z; Brown AW; de Andrade JA; Flaherty KR; Kaner RJ; King CS; Padilla ML; Noth I; Scholand MB; Shifren A; Nathan SD
BMC Pulm Med; 2020 Jul; 20(1):191. PubMed ID: 32664913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
